Cargando…

Icaritin: A Novel Natural Candidate for Hematological Malignancies Therapy

Hematological malignancies including leukemia and lymphoma can severely impact human health. With the current therapies combined with chemotherapy, stem cell transplantation, radiotherapy, and immunotherapy, the prognosis of hematologic malignancies improved significantly. However, most hematologica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Xiao-Jing, Xi, Ya-Ming, Li, Zi-Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458936/ https://www.ncbi.nlm.nih.gov/pubmed/31032347 http://dx.doi.org/10.1155/2019/4860268

Ejemplares similares

A comparative study on the in vitro and in vivo antitumor efficacy of icaritin and hydrous icaritin nanorods
por: Li, Haowen, et al.
Publicado: (2020)

Cytotoxic Effect of Icaritin and Its Mechanisms in Inducing Apoptosis in Human Burkitt Lymphoma Cell Line
por: Li, Zi-Jian, et al.
Publicado: (2014)

Icaritin Reduces Oral Squamous Cell Carcinoma Progression via the Inhibition of STAT3 Signaling
por: Yang, Jian-Guang, et al.
Publicado: (2017)

Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies
por: Sahin, Ugur, et al.
Publicado: (2019)

Icaritin inhibits decidualization of endometrial stromal cells
por: Le, Aiwen, et al.
Publicado: (2017)

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
por: Tian, Zheng, et al.
Publicado: (2021)

Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
por: Noh, Ji-Yoon, et al.
Publicado: (2020)

Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future
por: Lamb, Margaret G., et al.
Publicado: (2021)

Icaritin Provides Neuroprotection in Parkinson’s Disease by Attenuating Neuroinflammation, Oxidative Stress, and Energy Deficiency
por: Wu, Hao, et al.
Publicado: (2021)

Antiosteoporosis Effects, Pharmacokinetics, and Drug Delivery Systems of Icaritin: Advances and Prospects
por: Gao, Lifang, et al.
Publicado: (2022)

The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies
por: Zhu, Yu, et al.
Publicado: (2023)

Pharmacokinetics and metabolism of icaritin in rats by UPLC‐MS/MS
por: Huang, Zhen‐Wu, et al.
Publicado: (2019)

Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies
por: Pal, Dilipkumar, et al.
Publicado: (2023)

Dendritic Cell Therapies for Hematologic Malignancies
por: Weinstock, Matthew, et al.
Publicado: (2017)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

The journey of CAR-T therapy in hematological malignancies
por: Lu, Junru, et al.
Publicado: (2022)

Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
por: Lu, Yi, et al.
Publicado: (2022)

Investigating the effect of Icaritin on hepatocellular carcinoma based on network pharmacology
por: Xue, Zhong, et al.
Publicado: (2023)

The Hematology of Tomorrow Is Here—Preclinical Models Are Not: Cell Therapy for Hematological Malignancies
por: Arranz, Lorena
Publicado: (2022)

Icaritin Attenuates Lipid Accumulation by Increasing Energy Expenditure and Autophagy Regulated by Phosphorylating AMPK
por: Wu, Yue, et al.
Publicado: (2021)

Icaritin ameliorates RANKL-mediated osteoclastogenesis and ovariectomy-induced osteoporosis
por: Huang, Jun-ming, et al.
Publicado: (2023)

Natural product-derived icaritin exerts anti-glioblastoma effects by positively modulating estrogen receptor β
por: Li, Xiaowen, et al.
Publicado: (2020)

Icaritin enhances the efficacy of cetuximab against triple-negative breast cancer cells
por: Yin, Li, et al.
Publicado: (2020)

Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
por: Abbasi, Samane, et al.
Publicado: (2022)

Immunogenic Cell Death in Hematological Malignancy Therapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Correction to: Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
por: Lu, Yi, et al.
Publicado: (2023)

Erratum to: CAR T Cell Therapy for Hematological Malignancies
por: Yang, Xin, et al.
Publicado: (2021)

Interplay between cofactors and transcription factors in hematopoiesis and hematological malignancies
por: Wang, Zi, et al.
Publicado: (2021)

A Novel Semisynthetic Molecule Icaritin Stimulates Osteogenic Differentiation and Inhibits Adipogenesis of Mesenchymal Stem Cells
por: Sheng, Hui, et al.
Publicado: (2013)

Highly efficient bioconversion of icariin to icaritin by whole-cell catalysis
por: Lin, Yu, et al.
Publicado: (2023)

Icaritin Synergistically Enhances the Radiosensitivity of 4T1 Breast Cancer Cells
por: Hong, Jinsheng, et al.
Publicado: (2013)

Bioactive PLGA/tricalcium phosphate scaffolds incorporating phytomolecule icaritin developed for calvarial defect repair in rat model
por: Shi, Guang-Sen, et al.
Publicado: (2020)

Challenges and optimal strategies of CAR T therapy for hematological malignancies
por: Zhang, Yajing, et al.
Publicado: (2023)

Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies
por: Reagan, John L., et al.
Publicado: (2012)

Emerging Metabolic Targets in the Therapy of Hematological Malignancies
por: Leni, Zaira, et al.
Publicado: (2013)

Intestinal Microbes and Hematological Malignancies
por: Zhu, Yinghong, et al.
Publicado: (2023)

Icaritin induces lytic cytotoxicity in extranodal NK/T-cell lymphoma
por: Wu, Ting, et al.
Publicado: (2015)

Extracellular Vesicles in Hematological Malignancies: From Biology to Therapy
por: Caivano, Antonella, et al.
Publicado: (2017)

Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies
por: Lin, Wen-Ying, et al.
Publicado: (2020)

Current Progress in CAR-T Cell Therapy for Hematological Malignancies
por: Han, Donglei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mk6rfgpg171cufdb27q0acsseu